Exelixis Notches Win Against MSN In Cancer Drug Patent Trial
A Delaware federal judge on Thursday rejected MSN Laboratories' validity challenge to a patent on Exelixis Inc.'s blockbuster cancer drug Cabometyx, potentially keeping MSN's planned generic version off the market until...To view the full article, register now.
Already a subscriber? Click here to view full article